ANXA2
AR-V7
ATC code L01
Abagovomab
Abemaciclib
Abituzumab
Abrilumab
Acalabrutinib
Adagrasib
Adalimumab
Adecatumumab
Adipotide
Adjuvant therapy
Adoptive cell transfer
Adverse reaction
Afatinib
Afelimomab
Aflibercept
Alectinib
Alemtuzumab
Alpelisib
Amatuximab
American Medical Association
American Society of Health-System Pharmacists
Amivantamab
Anaplastic lymphoma kinase
Anatomical Therapeutic Chemical Classification System
Anatumomab mafenatox
Andecaliximab
Androgen receptor
Anifrolumab
Anrukinzumab
Anticoagulants
Antigen
Antineoplastic
Apolizumab
Asciminib
Ascrinvacumab
Aselizumab
Atezolizumab
Atezolizumab/hyaluronidase
Atorolimumab
Aumolertinib
Avapritinib
Avdoralimab
Avelumab
Axatilimab
Axitinib
BRAF (gene)
Balstilimab
Baricitinib
Basiliximab
Bavituximab
Bcr-abl fusion protein
Bectumomab
Belantamab mafodotin
Belimumab
Benralizumab
Bermekimab
Bertilimumab
Besilesomab
Bevacizumab
Bibcode (identifier)
Bimekizumab
Binimetinib
Biological half-life
Bivatuzumab mertansine
Bladder cancer
Bleselumab
Blinatumomab
Bosutinib
Botensilimab
Brazikumab
Brentuximab vedotin
Briakinumab
Brigatinib
Bristol-Myers Squibb
Brodalumab
Brontictuzumab
Bruton's tyrosine kinase
C-Met
CAS Registry Number
CD117
CD135
CD20
CD28
CD30
CD33
CD3 (immunology)
CD52
CDK inhibitor
CTLA-4
Cabozantinib
Camidanlumab tesirine
Camrelizumab
Canakinumab
Cancer immunotherapy
Cantuzumab mertansine
Cantuzumab ravtansine
Capmatinib
Carlumab
Carotuximab
Catumaxomab
Cedelizumab
Cediranib
Cemiplimab
Ceritinib
Certolizumab pegol
Cetuximab
ChEMBL
Checkpoint inhibitor induced colitis
ChemSpider
Chemical formula
Chimeric antibody
Cirmtuzumab
Citatuzumab bogatox
Cixutumumab
Clazakizumab
Clenoliximab
ClinicalTrials.gov
Clinical trial
Cobimetinib
Cofetuzumab pelidotin
Colorectal cancer
Conatumumab
Copanlisib
Corticosteroids
Cosibelimab
Crizanlizumab
Crizotinib
Cytotoxic T lymphocytes
Dabrafenib
Dacetuzumab
Daclizumab
Dacomitinib
DailyMed
Dalotuzumab
Dalpiciclib
Daratumumab
Dasatinib
Demcizumab
Demyelination
Dendritic cells
Denileukin diftitox
Denintuzumab mafodotin
Depatuxizumab mafodotin
Derek Lowe (chemist)
Detumomab
Dinutuximab
Dinutuximab beta
Doi (identifier)
Dostarlimab
Drozitumab
DrugBank
Drug nomenclature
Drugs.com
Duligotumab
Dupilumab
Durvalumab
Dusigitumab
Duvelisib
Duvortuxizumab
EML4
Ecromeximab
Eculizumab
Edrecolomab
Efalizumab
Eldelumab
Elimination half-life
Elotuzumab
Elranatamab
Elsilimomab
Emactuzumab
Emapalumab
Emibetuzumab
Encorafenib
Enfortumab vedotin
Enoblituzumab
Enoticumab
Ensituximab
Entrectinib
EpCAM
Epcoritamab
Epidermal growth factor receptor
Epitope
Epratuzumab
ErbB
Erdafitinib
Erlizumab
Erlotinib
Ertumaxomab
Etaracizumab
Etrolizumab
European Medicines Agency
Everolimus
Exotoxin
Faralimomab
Farletuzumab
Fedratinib
Fezakinumab
Fibroblast growth factor receptor
Ficlatuzumab
Figitumumab
Filgotinib
Flanvotumab
Fletikumab
Flotetuzumab
Fluoropyrimidine
Fontolizumab
Food and Drug Administration
Fragment antigen-binding
Fresolimumab
Frexalimab
Fruquintinib
Fusion protein
Futibatinib
Futuximab
Galiximab
Ganitumab
Gastrointestinal bleeding
Gavilimomab
Gefitinib
Gemtuzumab ozogamicin
Gene signature
Gevokizumab
Gilteritinib
Girentuximab
Glasdegib
Glembatumumab vedotin
Glofitamab
Golimumab
Gomiliximab
Guselkumab
HER2/neu
Health Canada
Hedgehog signaling pathway
Hepatocellular carcinoma
Hepatotoxicity
Hormone-refractory prostate cancer
Human
Humanized antibody
ISBN (identifier)
ISSN (identifier)
Ianalumab
Ibalizumab
Ibritumomab tiuxetan
Ibrutinib
Icotinib
Icrucumab
Idelalisib
Imatinib
Imgatuzumab
Immune checkpoint
Immune system
Immunoglobulin G
Immunosuppression
Inavolisib
Indatuximab ravtansine
Indium (111In) altumomab pentetate
Indium (111In) capromab pendetide
Indium (111In) igovomab
Indium (111In) satumomab pendetide
Inebilizumab
Infigratinib
Infliximab
Inolimomab
Inotuzumab ozogamicin
Interleukin
Interleukin 2
Intetumumab
Intravenous therapy
Iodine (131 I) derlotuximab biotin
Ipilimumab (data page)
Iratumumab
Irinotecan
Isatuximab
Istiratumab
Itolizumab
Ixekizumab
James P. Allison
Janus kinase
KEGG
KRAS
Keliximab
Labetuzumab
Lampalizumab
Lanadelumab
Lapatinib
Larotrectinib
Lasker Award
Lazertinib
Lebrikizumab
Leflunomide
Lemalesomab
Lenvatinib
Lenzilumab
Lerdelimumab
Lesion
Lestaurtinib
Letolizumab
Leukemia
Lexatumumab
Lifastuzumab vedotin
Ligelizumab
Lilotomab
Lintuzumab
Lirentelimab
Lirilumab
List of withdrawn drugs
Lokivetmab
Loncastuximab tesirine
Lorlatinib
Lorvotuzumab mertansine
Lucatumumab
Lulizumab pegol
Lumiliximab
Lumretuzumab
Lymph nodes
Lymphatic system
Lymphoma
MEN1
MTOR inhibitor
Malignant pleural mesothelioma
Mapatumumab
Margetuximab
Masitinib
Maslimomab
Matthew Krummel
Matuzumab
Mavrilimumab
Medarex
MedlinePlus
Mepolizumab
Metelimumab
Microsatellite instability
Midostaurin
Milatuzumab
Minretumomab
Mirikizumab
Mirvetuximab soravtansine
Mismatch repair cancer syndrome
Mitogen-activated protein kinase kinase
Mitumomab
Mobocertinib
Mogamulizumab
Molar mass
Momelotinib
Monoclonal antibodies
Monoclonal antibody
Monoclonal antibody therapy
Morolimumab
Mosunetuzumab
Motor paralysis
Moxetumomab pasudotox
Myasthenia gravis
Myeloid
Nacolomab tafenatox
Namilumab
Naptumomab estafenatox
Narnatumab
Natalizumab
Naxitamab
Necitumumab
Neoplasm
Neratinib
Nerelimomab
Nesvacumab
New York Times
Nilotinib
Nimotuzumab
Nintedanib
Nivolumab
Nivolumab/relatlimab
Nobel Prize in Physiology or Medicine
Non-receptor tyrosine kinase
Obinutuzumab
Ocaratuzumab
Ocrelizumab
Ocrelizumab/hyaluronidase
Odronextamab
Odulimomab
Ofatumumab
Olaratumab
Oleclumab
Olmutinib
Olokizumab
Omalizumab
Onartuzumab
Ontamalimab
Ontuxizumab
Oportuzumab monatox
Oregovomab
Orelabrutinib
Osimertinib
Otelixizumab
Otlertuzumab
Ovarian cancer
Oxaliplatin
Oxelumab
Ozoralizumab
PMC (identifier)
PMID (identifier)
PRO 140
Pacritinib
Palbociclib
Pamrevlumab
Panitumumab
Parsaclisib
Parsatuzumab
Pascolizumab
Pateclizumab
Patritumab
Pazopanib
Pembrolizumab
Pemigatinib
Pemtumomab
Peptides
Perakizumab
Pertuzumab
Pexelizumab
Pexidartinib
Pharmacokinetics
Phases of clinical research
Phosphatidylserine
Pi3K inhibitor
Pidilizumab
Pinatuzumab vedotin
Pirtobrutinib
Placulumab
Platelet-derived growth factor receptor
Plozalizumab
Polatuzumab vedotin
Polyneuropathy
Ponatinib
Pralsetinib
Pregnancy category
Prescription drug
Priliximab
Pritumumab
Proapoptotic
Prohibitin
Prolgolimab
Prostate cancer
Protein Data Bank
Public domain
Quilizumab
Quizartinib
RET proto-oncogene
RTK class III
Racotumomab
Radotinib
Radretumab
Ramucirumab
Ravulizumab
Receptor tyrosine kinase
Regorafenib
Regulation of therapeutic goods
Relatlimab
Renal cell carcinoma
Repotrectinib
Reslizumab
Retifanlimab
Revumenib
Ribociclib
Ridaforolimus
Rilotumumab
Ripretinib
Risankizumab
Rituximab
Robatumumab
Rociletinib
Rontalizumab
Rosmantuzumab
Route of administration
Rovalpituzumab tesirine
Rovelizumab
Rozanolixizumab
Ruplizumab
Ruxolitinib
S2CID (identifier)
Sabatolimab
Sacituzumab govitecan
Samalizumab
Sarilumab
Satralizumab
Science Translational Medicine
Secukinumab
Selpercatinib
Selumetinib
Semaxanib
Seribantumab
Serplulimab
Sibrotuzumab
Sifalimumab
Siltuximab
Simtuzumab
Siplizumab
Sirolimus
Sirukumab